Evidence based task 2.docx Evidence Based Practice and Applied Nursing Research 43670 Western Governors University (A1) Healthcare problem Our country is currently amid an Opioid use epidemic. In 2016 more than 42
...
Evidence based task 2.docx Evidence Based Practice and Applied Nursing Research 43670 Western Governors University (A1) Healthcare problem Our country is currently amid an Opioid use epidemic. In 2016 more than 42,000 people died in the United States from opiate overdoses. A variety of methods have been developed to curtail this crisis, including strategies like incarceration, counseling, and abstinence programs. One method that has been showing promise is Medication Assisted Treatment (MAT). According to (Moore, D. J., 2018) those who receive MAT are 75% less likely to have an addiction-related death than those who do not. Despite these short-term benefits, the long-term efficacy of MAT on opiate users is still vague. Most drugs in the US have rarely had studies that lasted for over two years, and anti-opioid drugs are no exception. As such, there is no prescribed length for the duration of MAT, and it is unclear if it needs to be utilized for a limited duration until the immediate withdrawal passes or if it should be continued as a life-long treatment like blood pressure medication or insulin (O'Neil, M. G., 2014). Without knowledge of how long these treatments should be maintained the efficacy of MAT as a viable option in the long-term care of opioid addicted patients is in doubt. Significance of the problem The significance of not knowing or having a set treatment length in place for MAT is crucial to its efficacy as a treatment for OUD. If MAT is not administered for long enough, relaps. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . .. .. . . . . . . . . . . . . . . . . . .. . . . .
[Show More]
